Glaukos Announces the Release of its 2023 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company's website here.

"I am proud to issue our fifth annual Sustainability Report on our progress to advance key corporate sustainability initiatives that we believe strengthen our organization and contribute to the betterment of communities we serve, while also helping to drive shareholder value over time," said Thomas Burns, Glaukos chairman and chief executive officer. "Continuing to grow and enhance our corporate sustainability initiatives is a key priority for us now and in the future as we remain focused on how we can better serve all of our stakeholders, including our employees, customers, patients, investors and communities around the globe."

Over the course of 2023, Glaukos undertook several actions to support and further improve its corporate sustainability efforts, including the following highlights:

• Donated over $10 million in products to underserved regions around the world.
• Established a second product distribution site, resulting in reduced shipping costs, the elimination of 6.4 million air miles and reduction in associated GHG emissions.
• Implemented new employee benefits and leadership development programs.
• Increased the number of patients who received assistance through one of Glaukos' patient assistance programs.
• Obtained ISO 14001 certification on its Burlington, MA site.
• Increased the number and percentage of women in its workforce.
• Launched Glaukos World Cafe Coffee n' Chats, a DEI-related learning session focused on exploring and discussing relevant topics.
• In conjunction with the FDA approval of iDose^® TR, launched the iDose your Dose philanthropic initiative, pledging that for every iDose TR sold, an equal number of iDose TR units will be made available for qualifying charitable donation requests in the U.S. and around the globe for recipients that satisfy independent eligibility requirements.

For additional information and highlights, please see Glaukos' 2023 Sustainability Report, which can be found on the company's website here.

Glaukos' ESG initiatives are overseen by the company's board of directors.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, our ability to achieve the sustainability targets identified in the sustainability report. Historical, current and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and process that continue to evolve, and assumptions that are subject to change in the future. The information included in, and any issues identified as material for purposes of this document may not be considered material for SEC reporting purposes. In the context of this disclosure, the term "material" is distinct from, and should not be confused with, such term as defined for SEC reporting purposes. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on February 23, 2024. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.